dominant negative form Search Results


92
Addgene inc tcf4e
Tcf4e, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tcf4e/product/Addgene inc
Average 92 stars, based on 1 article reviews
tcf4e - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier

90
Geron Bio dominant-negative form of mdia1
Dominant Negative Form Of Mdia1, supplied by Geron Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dominant-negative form of mdia1/product/Geron Bio
Average 90 stars, based on 1 article reviews
dominant-negative form of mdia1 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Cold Spring Harbor Laboratory Meetings cdna containing a dominant negative form of caspase-9 (casp9dn)
Cdna Containing A Dominant Negative Form Of Caspase 9 (Casp9dn), supplied by Cold Spring Harbor Laboratory Meetings, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdna containing a dominant negative form of caspase-9 (casp9dn)/product/Cold Spring Harbor Laboratory Meetings
Average 90 stars, based on 1 article reviews
cdna containing a dominant negative form of caspase-9 (casp9dn) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Schmid GmbH dominant-negative form of dynamin
Dominant Negative Form Of Dynamin, supplied by Schmid GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dominant-negative form of dynamin/product/Schmid GmbH
Average 90 stars, based on 1 article reviews
dominant-negative form of dynamin - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Cell Biolabs Inc adenovirus vectors containing dominant negative form p38 mapk (addnp38
Adenovirus Vectors Containing Dominant Negative Form P38 Mapk (Addnp38, supplied by Cell Biolabs Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/adenovirus vectors containing dominant negative form p38 mapk (addnp38/product/Cell Biolabs Inc
Average 90 stars, based on 1 article reviews
adenovirus vectors containing dominant negative form p38 mapk (addnp38 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Deltex Medical dominant-negative form of
Dominant Negative Form Of, supplied by Deltex Medical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dominant-negative form of/product/Deltex Medical
Average 90 stars, based on 1 article reviews
dominant-negative form of - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Namiki Shoji Co dominant-negative, kinase-deficient form of bmpr1a
Dominant Negative, Kinase Deficient Form Of Bmpr1a, supplied by Namiki Shoji Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dominant-negative, kinase-deficient form of bmpr1a/product/Namiki Shoji Co
Average 90 stars, based on 1 article reviews
dominant-negative, kinase-deficient form of bmpr1a - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Moberg Research Inc dominant-negative form of rab5
Dominant Negative Form Of Rab5, supplied by Moberg Research Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dominant-negative form of rab5/product/Moberg Research Inc
Average 90 stars, based on 1 article reviews
dominant-negative form of rab5 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Cell Biolabs Inc recombinant adenoviruses encoding dominant-negative form human erk2
Recombinant Adenoviruses Encoding Dominant Negative Form Human Erk2, supplied by Cell Biolabs Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant adenoviruses encoding dominant-negative form human erk2/product/Cell Biolabs Inc
Average 90 stars, based on 1 article reviews
recombinant adenoviruses encoding dominant-negative form human erk2 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Celgene flag-tagged adenovirus dominant negative form of mkk6
Flag Tagged Adenovirus Dominant Negative Form Of Mkk6, supplied by Celgene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/flag-tagged adenovirus dominant negative form of mkk6/product/Celgene
Average 90 stars, based on 1 article reviews
flag-tagged adenovirus dominant negative form of mkk6 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Inserm Transfert adenoviruses encoding a dominant-negative form (ad ampk-dn) of subunits α1 and α2 of ampk
A Measurement of mitochondrial function in A375 melanoma cells with a Seahorse XF Cell Mito stress test after 6 h of treatment with 5 μM CRO15, 10 mM metformin or DMSO used as control. At 20 min, cells are treated with oligomycin, an inhibitor of complex V of respiratory chain; at 50 min, with FCCP, which disrupts the mitochondrial membrane potential; and at 80 min, with Rotenone and antimycin A, inhibitors of complex I and III, respectively. B A375 cells were treated with 5 μM CRO15 (6H), 10 mM metformin (6H) for or 20 μM CCCP (20 min). Measurement of mitochondrial potential membrane was performed by flow cytometry with a TMRE probe. C Lysates from A375 melanoma cells exposed for the indicated durations to CRO15 were analyzed by western blotting using the indicated antibodies after cell fractionation. One representative experiment of three is shown. D Lysates from A375 cells treated with 5 μM CRO15 for the indicated durations were analyzed by western blotting using the indicated antibodies. One representative experiment of three is shown. E Lysates form A375 cells transduced with dominant negative <t>AMPK</t> <t>subunits</t> α1 and α2 for 24 h and treated with 5 μM CRO15 were analyzed by western blotting using the indicated antibodies. One representative experiment of three is shown. F Quantification of cell viability from E using trypan blue exclusion method. Results are expressed as percentages of DMSO control and data given as the means ± SEM of three independent experiments performed in triplicate. * p < 0.05; ** p < 0.01; *** p < 0.001.
Adenoviruses Encoding A Dominant Negative Form (Ad Ampk Dn) Of Subunits α1 And α2 Of Ampk, supplied by Inserm Transfert, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/adenoviruses encoding a dominant-negative form (ad ampk-dn) of subunits α1 and α2 of ampk/product/Inserm Transfert
Average 90 stars, based on 1 article reviews
adenoviruses encoding a dominant-negative form (ad ampk-dn) of subunits α1 and α2 of ampk - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Takeda dominant negative form of ikb
A Measurement of mitochondrial function in A375 melanoma cells with a Seahorse XF Cell Mito stress test after 6 h of treatment with 5 μM CRO15, 10 mM metformin or DMSO used as control. At 20 min, cells are treated with oligomycin, an inhibitor of complex V of respiratory chain; at 50 min, with FCCP, which disrupts the mitochondrial membrane potential; and at 80 min, with Rotenone and antimycin A, inhibitors of complex I and III, respectively. B A375 cells were treated with 5 μM CRO15 (6H), 10 mM metformin (6H) for or 20 μM CCCP (20 min). Measurement of mitochondrial potential membrane was performed by flow cytometry with a TMRE probe. C Lysates from A375 melanoma cells exposed for the indicated durations to CRO15 were analyzed by western blotting using the indicated antibodies after cell fractionation. One representative experiment of three is shown. D Lysates from A375 cells treated with 5 μM CRO15 for the indicated durations were analyzed by western blotting using the indicated antibodies. One representative experiment of three is shown. E Lysates form A375 cells transduced with dominant negative <t>AMPK</t> <t>subunits</t> α1 and α2 for 24 h and treated with 5 μM CRO15 were analyzed by western blotting using the indicated antibodies. One representative experiment of three is shown. F Quantification of cell viability from E using trypan blue exclusion method. Results are expressed as percentages of DMSO control and data given as the means ± SEM of three independent experiments performed in triplicate. * p < 0.05; ** p < 0.01; *** p < 0.001.
Dominant Negative Form Of Ikb, supplied by Takeda, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dominant negative form of ikb/product/Takeda
Average 90 stars, based on 1 article reviews
dominant negative form of ikb - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


A Measurement of mitochondrial function in A375 melanoma cells with a Seahorse XF Cell Mito stress test after 6 h of treatment with 5 μM CRO15, 10 mM metformin or DMSO used as control. At 20 min, cells are treated with oligomycin, an inhibitor of complex V of respiratory chain; at 50 min, with FCCP, which disrupts the mitochondrial membrane potential; and at 80 min, with Rotenone and antimycin A, inhibitors of complex I and III, respectively. B A375 cells were treated with 5 μM CRO15 (6H), 10 mM metformin (6H) for or 20 μM CCCP (20 min). Measurement of mitochondrial potential membrane was performed by flow cytometry with a TMRE probe. C Lysates from A375 melanoma cells exposed for the indicated durations to CRO15 were analyzed by western blotting using the indicated antibodies after cell fractionation. One representative experiment of three is shown. D Lysates from A375 cells treated with 5 μM CRO15 for the indicated durations were analyzed by western blotting using the indicated antibodies. One representative experiment of three is shown. E Lysates form A375 cells transduced with dominant negative AMPK subunits α1 and α2 for 24 h and treated with 5 μM CRO15 were analyzed by western blotting using the indicated antibodies. One representative experiment of three is shown. F Quantification of cell viability from E using trypan blue exclusion method. Results are expressed as percentages of DMSO control and data given as the means ± SEM of three independent experiments performed in triplicate. * p < 0.05; ** p < 0.01; *** p < 0.001.

Journal: Cell Death & Disease

Article Title: Discovery of a new molecule inducing melanoma cell death: dual AMPK/MELK targeting for novel melanoma therapies

doi: 10.1038/s41419-020-03344-6

Figure Lengend Snippet: A Measurement of mitochondrial function in A375 melanoma cells with a Seahorse XF Cell Mito stress test after 6 h of treatment with 5 μM CRO15, 10 mM metformin or DMSO used as control. At 20 min, cells are treated with oligomycin, an inhibitor of complex V of respiratory chain; at 50 min, with FCCP, which disrupts the mitochondrial membrane potential; and at 80 min, with Rotenone and antimycin A, inhibitors of complex I and III, respectively. B A375 cells were treated with 5 μM CRO15 (6H), 10 mM metformin (6H) for or 20 μM CCCP (20 min). Measurement of mitochondrial potential membrane was performed by flow cytometry with a TMRE probe. C Lysates from A375 melanoma cells exposed for the indicated durations to CRO15 were analyzed by western blotting using the indicated antibodies after cell fractionation. One representative experiment of three is shown. D Lysates from A375 cells treated with 5 μM CRO15 for the indicated durations were analyzed by western blotting using the indicated antibodies. One representative experiment of three is shown. E Lysates form A375 cells transduced with dominant negative AMPK subunits α1 and α2 for 24 h and treated with 5 μM CRO15 were analyzed by western blotting using the indicated antibodies. One representative experiment of three is shown. F Quantification of cell viability from E using trypan blue exclusion method. Results are expressed as percentages of DMSO control and data given as the means ± SEM of three independent experiments performed in triplicate. * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: Adenoviruses encoding a dominant-negative form (Ad AMPK-DN) of subunits α1 and α2 of AMPK were a generous gift of Dr. Foufelle (INSERM, UMR-S 872, Paris, France).

Techniques: Control, Membrane, Flow Cytometry, Western Blot, Cell Fractionation, Transduction, Dominant Negative Mutation

A Scatter plot representing the percentage of kinase inhibition and their Z′ factor measured during two independent in vitro kinome assay with 1 μM CRO15. B Immunofluorescence pictures of CT26 cancer cells treated with 5 μM CRO15 for 2 h. MELK was labeled with a specific antibody (in red), CRO15 was coupled to a fluorescent tag (in green) and nuclei were stained with DAPI (in blue). C In vitro test of kinase activity using recombinant MELK protein treated with CRO15 with the MELK inhibitor OTS167. D A375 cells were infected with MELK adenovirus for 24 h. For the pull down assay, cells lysates were incubated overnight with 100 μM Biotin-CRO15 or its inactive analog MTF465. For Biotin precipitation, cells were treated for 2 h with 20 μM Biotin-CRO15 or MTF465 before lysis and western blot analysis with the indicated antibodies. One representative experiment of three is shown. E and F A375 cells were treated with 5 μM CRO15 with the indicated durations, and lysates were analyzed by western blotting using the indicated antibodies. One representative experiment of three is shown. G A375 cells were transfected with siRNA directed against AMPK α1 and AMPK α2 (20 nM each) or 40 nM of control siRNA. Twenty-four hours later, cells were infected with a MELK adenovirus or a control adenovirus before treatment with 5 µM of CRO15. After 24H, viable cells were counted using the trypan blue dye exclusion method ( n = 3) (right panel). In parallel, cell lysates were analyzed by western blotting with the indicated antibodies (left panel). One representative experiment of three is shown.

Journal: Cell Death & Disease

Article Title: Discovery of a new molecule inducing melanoma cell death: dual AMPK/MELK targeting for novel melanoma therapies

doi: 10.1038/s41419-020-03344-6

Figure Lengend Snippet: A Scatter plot representing the percentage of kinase inhibition and their Z′ factor measured during two independent in vitro kinome assay with 1 μM CRO15. B Immunofluorescence pictures of CT26 cancer cells treated with 5 μM CRO15 for 2 h. MELK was labeled with a specific antibody (in red), CRO15 was coupled to a fluorescent tag (in green) and nuclei were stained with DAPI (in blue). C In vitro test of kinase activity using recombinant MELK protein treated with CRO15 with the MELK inhibitor OTS167. D A375 cells were infected with MELK adenovirus for 24 h. For the pull down assay, cells lysates were incubated overnight with 100 μM Biotin-CRO15 or its inactive analog MTF465. For Biotin precipitation, cells were treated for 2 h with 20 μM Biotin-CRO15 or MTF465 before lysis and western blot analysis with the indicated antibodies. One representative experiment of three is shown. E and F A375 cells were treated with 5 μM CRO15 with the indicated durations, and lysates were analyzed by western blotting using the indicated antibodies. One representative experiment of three is shown. G A375 cells were transfected with siRNA directed against AMPK α1 and AMPK α2 (20 nM each) or 40 nM of control siRNA. Twenty-four hours later, cells were infected with a MELK adenovirus or a control adenovirus before treatment with 5 µM of CRO15. After 24H, viable cells were counted using the trypan blue dye exclusion method ( n = 3) (right panel). In parallel, cell lysates were analyzed by western blotting with the indicated antibodies (left panel). One representative experiment of three is shown.

Article Snippet: Adenoviruses encoding a dominant-negative form (Ad AMPK-DN) of subunits α1 and α2 of AMPK were a generous gift of Dr. Foufelle (INSERM, UMR-S 872, Paris, France).

Techniques: Inhibition, In Vitro, Immunofluorescence, Labeling, Staining, Activity Assay, Recombinant, Infection, Pull Down Assay, Incubation, Lysis, Western Blot, Transfection, Control

A A375 cells were treated with 5 μM CRO15 for the indicated duration. Lysates were analyzed by western blotting with the indicated antibodies. One representative experiment of three is shown. B Immunofluorescence pictures of A375 melanoma cells treated with DMSO, 5 μM CRO15 or 400 nM of the autophagy inducer rapamycin for 6 h. LC3B was labeled with antibody (green), and DNA was visualized with DAPI (blue). C A375 melanoma cells were treated for 24 h with 5 μM CRO15, 5 μM PLX4032 or with 1 μM of the pan-kinase inhibitor staurosporine for 6 h used as positive control of apoptosis induction. Cells were analyzed by flow cytometry using a specific antibody against Caspase 3 active protein conjugated with FITC (upper panel) or Annexin V conjugated with ALEXA and DAPI (lower panel) or against. * p < 0.05; ** p < 0.01; *** p < 0.001. D A375 cells were infected with dominant negative adenoviruses against α1 and α2 AMPK subunits for 24 h before transfection with sip53 for another 24 h. Cells was determined by trypan blue staining after a 24 h treatment with 5 μM CRO15 or DMSO control. E A375 cells were infected with dominant negative adenoviruses against α1 and α2 AMPK subunits for 24 h and were transfected with sip53 for another 24 h. Cells were treated with 5 μM CRO15 for the indicated durations, and lysates were analyzed by western blot with the indicated antibodies. One experiment of three is shown. F A375 cells were treated with 5 μM CRO15 for the indicated durations, and lysates were analyzed by western blotting with the indicated antibodies. One representative experiment of three is shown. G A375 cells were transfected with siREDD1 for 24 h and then treated with 5 μM CRO15 for 24 h before cell viability was determined using the trypan blue exclusion method. H . A375 cells were transfected with siREDD1 for 24 h and then treated with 5 μM CRO15 for the indicated duration. Lysates were analyzed by western blotting with the indicated antibodies. One representative experiment of three is shown. For D and G , the results are expressed as percentages of the control and data given as the means ± SEM of three independent experiments performed in triplicate. * p < 0.05; ** p < 0.01; *** p < 0.001.

Journal: Cell Death & Disease

Article Title: Discovery of a new molecule inducing melanoma cell death: dual AMPK/MELK targeting for novel melanoma therapies

doi: 10.1038/s41419-020-03344-6

Figure Lengend Snippet: A A375 cells were treated with 5 μM CRO15 for the indicated duration. Lysates were analyzed by western blotting with the indicated antibodies. One representative experiment of three is shown. B Immunofluorescence pictures of A375 melanoma cells treated with DMSO, 5 μM CRO15 or 400 nM of the autophagy inducer rapamycin for 6 h. LC3B was labeled with antibody (green), and DNA was visualized with DAPI (blue). C A375 melanoma cells were treated for 24 h with 5 μM CRO15, 5 μM PLX4032 or with 1 μM of the pan-kinase inhibitor staurosporine for 6 h used as positive control of apoptosis induction. Cells were analyzed by flow cytometry using a specific antibody against Caspase 3 active protein conjugated with FITC (upper panel) or Annexin V conjugated with ALEXA and DAPI (lower panel) or against. * p < 0.05; ** p < 0.01; *** p < 0.001. D A375 cells were infected with dominant negative adenoviruses against α1 and α2 AMPK subunits for 24 h before transfection with sip53 for another 24 h. Cells was determined by trypan blue staining after a 24 h treatment with 5 μM CRO15 or DMSO control. E A375 cells were infected with dominant negative adenoviruses against α1 and α2 AMPK subunits for 24 h and were transfected with sip53 for another 24 h. Cells were treated with 5 μM CRO15 for the indicated durations, and lysates were analyzed by western blot with the indicated antibodies. One experiment of three is shown. F A375 cells were treated with 5 μM CRO15 for the indicated durations, and lysates were analyzed by western blotting with the indicated antibodies. One representative experiment of three is shown. G A375 cells were transfected with siREDD1 for 24 h and then treated with 5 μM CRO15 for 24 h before cell viability was determined using the trypan blue exclusion method. H . A375 cells were transfected with siREDD1 for 24 h and then treated with 5 μM CRO15 for the indicated duration. Lysates were analyzed by western blotting with the indicated antibodies. One representative experiment of three is shown. For D and G , the results are expressed as percentages of the control and data given as the means ± SEM of three independent experiments performed in triplicate. * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: Adenoviruses encoding a dominant-negative form (Ad AMPK-DN) of subunits α1 and α2 of AMPK were a generous gift of Dr. Foufelle (INSERM, UMR-S 872, Paris, France).

Techniques: Western Blot, Immunofluorescence, Labeling, Positive Control, Flow Cytometry, Infection, Dominant Negative Mutation, Transfection, Staining, Control